Endothelin antagonists for hypertension: has their time finally arrived?
Clinical Science · 2025
DOI: 10.1042/cs20255853 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, 2025. Verfasst von Ernesto L Schiffrin. Beteiligte Einrichtung: Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General H…. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Endothelin Receptor Antagonists, Endothelin A Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There have been few new treatments introduced for hypertension in the last thirty years. The endothelin (ET) system was discovered in 1988, and in the following years, it was demonstrated that it participated in the elevation of blood pressure and vascular remodeling in experimental models of hypertension, particularly those with more severe forms of hypertension. Several selective and dual antagonists of ETA receptors (ETARs) and ETB receptors (ETBRs) were developed, but none reached marketing for human hypertension. Following a successful trial in resistant hypertension, a novel antihypertensive agent has been approved in Europe and in the U.S.A.: the dual ETAR/ETBR antagonist aprocitentan, which was recently approved for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Thus, the time has finally arrived for ET antagonists in hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, MGill University, Montreal, Quebec, Canada.
ORCID-Profile: Ernesto L Schiffrin
Zitieren
APA
Schiffrin, E. L. (2025). Endothelin antagonists for hypertension: has their time finally arrived?. Clinical Science. https://doi.org/10.1042/cs20255853
Vancouver
Schiffrin EL. Endothelin antagonists for hypertension: has their time finally arrived?. Clinical Science. 2025. doi:10.1042/cs20255853
BibTeX
@article{Schiffrin2025,
author = {Schiffrin, Ernesto L},
title = {Endothelin antagonists for hypertension: has their time finally arrived?},
journal = {Clinical Science},
year = {2025},
doi = {10.1042/cs20255853}
}
EUVIMED